Dextech Medical Bilan de santé

Santé financière contrôle des critères 6/6

Dextech Medical possède un total de capitaux propres de SEK28.5M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK29.2M et de SEK687.0K.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 17.99m
Fonds propres	SEK 28.47m
Total du passif	SEK 687.00k
Total des actifs	SEK 29.16m

Mises à jour récentes de la santé financière

Recent updates

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Jan 10

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Sep 20

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Jun 03

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

Feb 17

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Dec 12

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de DEX ( SEK18.6M ) dépassent ses passifs à court terme ( SEK687.0K ).

Passif à long terme: DEX n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: DEX est sans dette.

Réduire la dette: DEX n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: DEX dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: DEX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 4.8 % chaque année

Dextech Medical Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Recent updates

First quarter 2025 earnings released: kr0.062 loss per share (vs kr0.05 loss in 1Q 2024)

Dextech Medical AB to Report First Half, 2025 Results on Feb 27, 2025

Dextech Medical AB to Report Q1, 2025 Results on Oct 24, 2024

Dextech Medical AB Announces Continued Positive Results from Myeloma Study

Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023)

DexTech Medical Announces New Positive Results from the Myeloma Study

New major risk - Market cap size

Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Share price stability

Dextech Medical AB Announces Positive Results from the Myeloma Study

DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023)

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022)

New minor risk - Share price stability

Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022)

Dextech Medical AB to Report Fiscal Year 2024 Results on Aug 30, 2024

No independent directors

First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022)

Dextech Medical AB Announces Upcoming Multiple Myeloma Study

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021)

Dextech Medical AB to Report Q1, 2023 Results on Oct 27, 2022

Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021)

No independent directors

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

DexTech Medical AB Plans New Clinical Study on Multiple Myeloma

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

DexTech Medical AB Confirms Very Positive Results from Myeloma Studies

Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020)

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

New 90-day high: kr59.40

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020)

DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma

New 90-day low: kr45.20

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

First quarter earnings released

Full year earnings released - kr0.52 loss per share

Full year earnings released - kr0.52 loss per share

New 90-day low - kr38.00

New 90-day low - kr42.00

New 90-day low - kr45.00

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines